A Systematic Review of the Clinical and Cost-Effectiveness of Memantine in Patients with Moderately Severe to Severe Alzheimer's Disease

Author： Kirby Joanna   Green Colin   Loveman Emma   Clegg Andrew   Picot Joanna   Takeda Andrea   Payne Elizabeth  

Publisher： Adis International

ISSN： 1170-229X

Source： Drugs & Aging, Vol.23, Iss.3, 2006-01, pp. : 227-240

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Memantine in Moderately Severe to Severe Alzheimer’s Disease: A Markov Model in Finland

By François C.  

Clinical Drug Investigation, Vol. 24, Iss. 7, 2004-01 ,pp. : 373-384

Adis International

Access to resources Recommend Favorite

Memantine in Moderately-Severe-to-Severe Alzheimer's Disease: A Postmarketing Surveillance Study

By Clerici Francesca  

Drugs & Aging, Vol. 26, Iss. 4, 2009-05 ,pp. : 321-332

Adis International

Access to resources Recommend Favorite

Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer's Disease

By Wimo A.  

PharmacoEconomics, Vol. 21, Iss. 5, 2003-01 ,pp. : 327-340

Adis International

Access to resources Recommend Favorite

Memantine cost saving in moderately-severe to severe AD

By  

Inpharma, Vol. 1, Iss. 1450, 2004-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer's Disease

By Green Colin   Picot Joanna   Loveman Emma   Takeda Andrea   Kirby Jo   Clegg Andrew  

PharmacoEconomics, Vol. 23, Iss. 12, 2005-01 ,pp. : 1271-1282

Adis International

Access to resources Recommend Favorite